Engineered nanoparticles against MDR in cancer: The state of the art and its prospective
Identifieur interne : 000972 ( Pmc/Checkpoint ); précédent : 000971; suivant : 000973Engineered nanoparticles against MDR in cancer: The state of the art and its prospective
Auteurs : Javed Ahmad [Inde] ; Sohail Akhter [France] ; Nigel H. Greig [États-Unis] ; Mohammad Amjad Kamal [Arabie saoudite, Australie] ; Patrick Midoux [France] ; Chantal Pichon [France]Source :
- Current pharmaceutical design [ 1381-6128 ] ; 2016.
Abstract
Cancer is a highly heterogeneous disease, both within a single patient as well as between patients, and is the leading cause of death worldwide. A variety of mono and combinational therapies, including chemotherapy, have been developed and refined over recent years for its effective treatment. However, the evolution of chemotherapeutic resistance or multidrug resistance (MDR) in cancer has become a major challenge to successful chemotherapy. MDR is a complex process that combines multifaceted non-cellular and cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decades has reached the point where smartly designed nanoparticles with targeting ligands can aid successful chemotherapy by preferentially accumulating within the tumor region through means of active and passive targeting to overcome MDR, and simultaneously reduce the off-target accumulation of their payload. Such nanoparticle formulations – sometimes termed nanomedicines - are at different stages of cancer clinical trials and show promise in resistant cases. Nanoparticles as chemotherapeutics carriers provide the opportunity to have multiple payloads of drug and/or imaging agents for combinational and theranostic therapy. Moreover, nanotechnology has the potential to combine new treatment strategies, such as near-infrared (NIR), magnetic resonance imaging (MRI), and high intensity focused ultrasound (HIFU) into cancer chemotherapy and imaging. Here we discuss the cellular/non-cellular factors that underpin MDR in cancer, and the potential of nanomedicines to combat MDR, along with recent advances in combining nanotechnology with other approaches in cancer therapy.
Url:
PubMed: 27319945
PubMed Central: 5182049
Affiliations:
- Arabie saoudite, Australie, France, Inde, États-Unis
- Centre-Val de Loire, Maryland, Région Centre
- Orléans
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:5182049Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Engineered nanoparticles against MDR in cancer: The state of the art and its prospective</title>
<author><name sortKey="Ahmad, Javed" sort="Ahmad, Javed" uniqKey="Ahmad J" first="Javed" last="Ahmad">Javed Ahmad</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010</wicri:regionArea>
<wicri:noRegion>UP-229010</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Akhter, Sohail" sort="Akhter, Sohail" uniqKey="Akhter S" first="Sohail" last="Akhter">Sohail Akhter</name>
<affiliation wicri:level="1"><nlm:aff id="A2">LE STUDIUM<sup>®</sup>
Loire Valley Institute for Advanced Studies, Centre-Val de Loire region, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea> Loire Valley Institute for Advanced Studies, Centre-Val de Loire region</wicri:regionArea>
<wicri:noRegion>Centre-Val de Loire region</wicri:noRegion>
<wicri:noRegion>Centre-Val de Loire region</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="A3">Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea>
<placeName><region type="region">Centre-Val de Loire</region>
<region type="old region">Région Centre</region>
<settlement type="city">Orléans</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Greig, Nigel H" sort="Greig, Nigel H" uniqKey="Greig N" first="Nigel H." last="Greig">Nigel H. Greig</name>
<affiliation wicri:level="2"><nlm:aff id="A4">Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name>
<affiliation wicri:level="1"><nlm:aff id="A5">Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia</nlm:aff>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589</wicri:regionArea>
<wicri:noRegion>Jeddah 21589</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A6">Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770</wicri:regionArea>
<wicri:noRegion>NSW 2770</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Midoux, Patrick" sort="Midoux, Patrick" uniqKey="Midoux P" first="Patrick" last="Midoux">Patrick Midoux</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea>
<placeName><region type="region">Centre-Val de Loire</region>
<region type="old region">Région Centre</region>
<settlement type="city">Orléans</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pichon, Chantal" sort="Pichon, Chantal" uniqKey="Pichon C" first="Chantal" last="Pichon">Chantal Pichon</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea>
<placeName><region type="region">Centre-Val de Loire</region>
<region type="old region">Région Centre</region>
<settlement type="city">Orléans</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27319945</idno>
<idno type="pmc">5182049</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182049</idno>
<idno type="RBID">PMC:5182049</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">002195</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002195</idno>
<idno type="wicri:Area/Pmc/Curation">002046</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002046</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000972</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000972</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Engineered nanoparticles against MDR in cancer: The state of the art and its prospective</title>
<author><name sortKey="Ahmad, Javed" sort="Ahmad, Javed" uniqKey="Ahmad J" first="Javed" last="Ahmad">Javed Ahmad</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010</wicri:regionArea>
<wicri:noRegion>UP-229010</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Akhter, Sohail" sort="Akhter, Sohail" uniqKey="Akhter S" first="Sohail" last="Akhter">Sohail Akhter</name>
<affiliation wicri:level="1"><nlm:aff id="A2">LE STUDIUM<sup>®</sup>
Loire Valley Institute for Advanced Studies, Centre-Val de Loire region, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea> Loire Valley Institute for Advanced Studies, Centre-Val de Loire region</wicri:regionArea>
<wicri:noRegion>Centre-Val de Loire region</wicri:noRegion>
<wicri:noRegion>Centre-Val de Loire region</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="A3">Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea>
<placeName><region type="region">Centre-Val de Loire</region>
<region type="old region">Région Centre</region>
<settlement type="city">Orléans</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Greig, Nigel H" sort="Greig, Nigel H" uniqKey="Greig N" first="Nigel H." last="Greig">Nigel H. Greig</name>
<affiliation wicri:level="2"><nlm:aff id="A4">Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name>
<affiliation wicri:level="1"><nlm:aff id="A5">Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia</nlm:aff>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589</wicri:regionArea>
<wicri:noRegion>Jeddah 21589</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A6">Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770</wicri:regionArea>
<wicri:noRegion>NSW 2770</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Midoux, Patrick" sort="Midoux, Patrick" uniqKey="Midoux P" first="Patrick" last="Midoux">Patrick Midoux</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea>
<placeName><region type="region">Centre-Val de Loire</region>
<region type="old region">Région Centre</region>
<settlement type="city">Orléans</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pichon, Chantal" sort="Pichon, Chantal" uniqKey="Pichon C" first="Chantal" last="Pichon">Chantal Pichon</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea>
<placeName><region type="region">Centre-Val de Loire</region>
<region type="old region">Région Centre</region>
<settlement type="city">Orléans</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Current pharmaceutical design</title>
<idno type="ISSN">1381-6128</idno>
<idno type="eISSN">1873-4286</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Cancer is a highly heterogeneous disease, both within a single patient as well as between patients, and is the leading cause of death worldwide. A variety of mono and combinational therapies, including chemotherapy, have been developed and refined over recent years for its effective treatment. However, the evolution of chemotherapeutic resistance or multidrug resistance (MDR) in cancer has become a major challenge to successful chemotherapy. MDR is a complex process that combines multifaceted non-cellular and cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decades has reached the point where smartly designed nanoparticles with targeting ligands can aid successful chemotherapy by preferentially accumulating within the tumor region through means of active and passive targeting to overcome MDR, and simultaneously reduce the off-target accumulation of their payload. Such nanoparticle formulations – sometimes termed nanomedicines - are at different stages of cancer clinical trials and show promise in resistant cases. Nanoparticles as chemotherapeutics carriers provide the opportunity to have multiple payloads of drug and/or imaging agents for combinational and theranostic therapy. Moreover, nanotechnology has the potential to combine new treatment strategies, such as near-infrared (NIR), magnetic resonance imaging (MRI), and high intensity focused ultrasound (HIFU) into cancer chemotherapy and imaging. Here we discuss the cellular/non-cellular factors that underpin MDR in cancer, and the potential of nanomedicines to combat MDR, along with recent advances in combining nanotechnology with other approaches in cancer therapy.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9602487</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21197</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Pharm Des</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr. Pharm. Des.</journal-id>
<journal-title-group><journal-title>Current pharmaceutical design</journal-title>
</journal-title-group>
<issn pub-type="ppub">1381-6128</issn>
<issn pub-type="epub">1873-4286</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">27319945</article-id>
<article-id pub-id-type="pmc">5182049</article-id>
<article-id pub-id-type="manuscript">NIHMS837362</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Engineered nanoparticles against MDR in cancer: The state of the art and its prospective</article-title>
</title-group>
<contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ahmad</surname>
<given-names>Javed</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes"><name><surname>Akhter</surname>
<given-names>Sohail</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Greig</surname>
<given-names>Nigel H.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kamal</surname>
<given-names>Mohammad Amjad</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Midoux</surname>
<given-names>Patrick</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Pichon</surname>
<given-names>Chantal</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India</aff>
<aff id="A2"><label>2</label>
LE STUDIUM<sup>®</sup>
Loire Valley Institute for Advanced Studies, Centre-Val de Loire region, France</aff>
<aff id="A3"><label>3</label>
Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</aff>
<aff id="A4"><label>4</label>
Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224, USA</aff>
<aff id="A5"><label>5</label>
Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia</aff>
<aff id="A6"><label>6</label>
Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia</aff>
<author-notes><corresp id="CR1"><label>*</label>
<bold>Author for correspondence</bold>
, <bold>Sohail Akhter</bold>
, <italic>Senior Fellow</italic>
of LE STUDIUM<sup>®</sup>
Loire Valley Institute for Advanced Studies, Centre-Val de Loire region, France at Nucleic acids transfer by non-viral methods, Centre de BiophysiqueMoléculaire, CNRS UPR4301, Orléans, France, <email>sohailakhtermph@gmail.com</email>
, Contact: +33699908746
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>21</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub"><year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>23</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>22</volume>
<issue>28</issue>
<fpage>4360</fpage>
<lpage>4373</lpage>
<abstract><p id="P1">Cancer is a highly heterogeneous disease, both within a single patient as well as between patients, and is the leading cause of death worldwide. A variety of mono and combinational therapies, including chemotherapy, have been developed and refined over recent years for its effective treatment. However, the evolution of chemotherapeutic resistance or multidrug resistance (MDR) in cancer has become a major challenge to successful chemotherapy. MDR is a complex process that combines multifaceted non-cellular and cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decades has reached the point where smartly designed nanoparticles with targeting ligands can aid successful chemotherapy by preferentially accumulating within the tumor region through means of active and passive targeting to overcome MDR, and simultaneously reduce the off-target accumulation of their payload. Such nanoparticle formulations – sometimes termed nanomedicines - are at different stages of cancer clinical trials and show promise in resistant cases. Nanoparticles as chemotherapeutics carriers provide the opportunity to have multiple payloads of drug and/or imaging agents for combinational and theranostic therapy. Moreover, nanotechnology has the potential to combine new treatment strategies, such as near-infrared (NIR), magnetic resonance imaging (MRI), and high intensity focused ultrasound (HIFU) into cancer chemotherapy and imaging. Here we discuss the cellular/non-cellular factors that underpin MDR in cancer, and the potential of nanomedicines to combat MDR, along with recent advances in combining nanotechnology with other approaches in cancer therapy.</p>
</abstract>
<kwd-group><kwd>Multidrug resistance</kwd>
<kwd>MDR</kwd>
<kwd>efflux transporter</kwd>
<kwd>Nanoparticles</kwd>
<kwd>passive targeting</kwd>
<kwd>active targeting</kwd>
<kwd>pH-sensitive</kwd>
<kwd>HIFU</kwd>
<kwd>Combinational drug targeting</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
<affiliations><list><country><li>Arabie saoudite</li>
<li>Australie</li>
<li>France</li>
<li>Inde</li>
<li>États-Unis</li>
</country>
<region><li>Centre-Val de Loire</li>
<li>Maryland</li>
<li>Région Centre</li>
</region>
<settlement><li>Orléans</li>
</settlement>
</list>
<tree><country name="Inde"><noRegion><name sortKey="Ahmad, Javed" sort="Ahmad, Javed" uniqKey="Ahmad J" first="Javed" last="Ahmad">Javed Ahmad</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Akhter, Sohail" sort="Akhter, Sohail" uniqKey="Akhter S" first="Sohail" last="Akhter">Sohail Akhter</name>
</noRegion>
<name sortKey="Akhter, Sohail" sort="Akhter, Sohail" uniqKey="Akhter S" first="Sohail" last="Akhter">Sohail Akhter</name>
<name sortKey="Midoux, Patrick" sort="Midoux, Patrick" uniqKey="Midoux P" first="Patrick" last="Midoux">Patrick Midoux</name>
<name sortKey="Pichon, Chantal" sort="Pichon, Chantal" uniqKey="Pichon C" first="Chantal" last="Pichon">Chantal Pichon</name>
</country>
<country name="États-Unis"><region name="Maryland"><name sortKey="Greig, Nigel H" sort="Greig, Nigel H" uniqKey="Greig N" first="Nigel H." last="Greig">Nigel H. Greig</name>
</region>
</country>
<country name="Arabie saoudite"><noRegion><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000972 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000972 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Pmc |étape= Checkpoint |type= RBID |clé= PMC:5182049 |texte= Engineered nanoparticles against MDR in cancer: The state of the art and its prospective }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:27319945" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |